[1] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
[2] WANG Q,LI L,LI C Y,et al.SIRT3 protects cells from hypoxia via PGC-1α-and MnSOD-dependent pathways[J].Neuroscience,2015,12(286):109-121.
[3] CLAYCOMBE K J,ROEMMICH J N,JOHNSON L,et al.Skeletal muscle Sirt3 expression and mitochondrial respiration are regulated by a prenatal low-protein diet[J].J Nutr Biochem,2015,26(2):184-189.
[4] 翟雅娜.MK、p53、bcl-2在乳腺癌患者中的表达及其相关性分析[J].现代医学,2016,44(12):1702-1705.
[5] SONG Y,SHI J,WU Y,et al.Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3[J].Chin Med J(Engl),2014,127(8):1523-1529.
[6] BAO J,LU Z,JOSEPH J J,et al.Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms[J].J Cell Biochem,2010,110(1):238-247.
[7] TEODORO J S,DUARTE F V,GOMES A P,et al.Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats:a possible role for SirT3 activation[J].Mitochondrion,2013,13(6):637-646.表3乳腺癌患者OS单因素Cox回归分析Tab 3 Singl Cox regression analysis of OS in patients with breast cancer临床特征偏回归系数标准误P值HR(95%CI)年龄(1=<45岁,2= ≥ 45岁)0.160.1210.0571.18(0.88~2.42)月经(1=未绝经,2=绝经)0.140.2060.4911.15(0.77~1.73)肿瘤大小(1=<2 cm,2= ≥ 2 cm)1.660.240<0.0015.24(3.27~8.39)淋巴结转移(1=无,2=有)4.270.535<0.00171.49(25.05~204.07)组织学分级(Ⅰ=1,Ⅱ、Ⅲ=2)2.670.256<0.00114.39(8.71~23.76)病理组织分型(1=导管癌,2=小叶癌)-3.400.447<0.0010.34(0.01~0.08)ER(1=阴性,2=阳性)2.830.297<0.00116.99(9.49~30.41)PR(1=阴性,2=阳性)-2.670.273<0.0010.07(0.04~0.12)Her-2(1=阴性,2=阳性)-2.680.258<0.0010.06(0.03~0.10)SIRT3表达(1=低表达,2=高表达)0.620.2220.0051.87(1.21~2.88)表4乳腺癌患者OS多因素Cox回归分析Tab 4 Multiple Cox regression analysis of OS in patient with breast cancer临床特征偏回归系数标准误P值HR(95%CI)肿瘤大小(1=<2 cm,2= ≥ 2 cm)3.511.2940.0133.60(2.66~424.42)淋巴结转移(1=无,2=有)1.360.8660.013.91(1.13~9.36)SIRT3表达(1=低表达,2=高表达)0.700.3180.032.00(1.07~3.74)图2 SIRT3高表达组和低表达组的乳腺癌患者生存分析Fig 2 Analysis of OS between SIRT3 high expression group and SIRT3 low expression group
[8] DRANSFELD C L,ALBORZINIA H,WOLFL S,et al.SIRT3 SNPs validation in 640 individuals,functional analyses and new insights into SIRT3 stability[J].Int J Oncol,2010,36(4):955-960.
[9] DISCH J S,EVINDAR G,CHIU C H,et al.Discovery of thieno[3,2-d] pyrimdine-6-carboxamides as potent inhibitors of SIRT1,SIRT2,and SIRT3[J].J Med Chem,2013,56(9):3666-3679.
[10] LIU T F,VACHHARAJANI V,MILLET P,et al.Sequential actions of SIRT1-RELB SIRT3 coordinate nuclear-mitochondrial communication during immunometabolic adaptation to acute inflammation and sepsis[J].J Biol Chem,2015,290(1):396-408.
[11] 李利娟,张景华,魏丽娟,等.43例分泌性乳腺癌临床分析[J].中华普通外科杂志,2014,29(9):684-687.
[12] 李生兰,纪少春,栾宏辉,等.早期乳腺癌患者术后放化疗后不同基因分型的预后分析[J].现代肿瘤医学,2015,23(2):225-228.
[13] 罗舟,徐涛,秦建伟,等.前哨淋巴结活组织检查指导乳腺癌腋窝淋巴结清扫问题的思考[J].中华乳腺病杂志:电子版,2014,12(1):55-58.
[14] 石琴芳,冯梦宇,罗琨,等.乳腺癌组织Ras相关区域家族1A基因启动子甲基化状态及临床意义[J].中华实验外科杂志,2015,32(1):154-156.
[15] 刘海芳,高杨,姜楠,等.乳腺癌超声表现与生物学指标的相关性及对临床治疗的指导意义[J].中国医药,2015,10(1):1-4.
[16] HE S,HE C,YUAN H,et al.The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients[J].Cell Physiol Biochem,2014,34(6):2061-2069. |